Maxigen Biotech Inc. (TPE:1783)

Maxigen Biotech Balance Sheet

Financials in millions TWD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	731.12	639.05	431.08	790.95	513.31	209.76
Short-Term Investments	-	-	-	8.82	13.84	-
Cash & Short-Term Investments	731.12	639.05	431.08	799.76	527.15	209.76
Cash Growth	34.46%	48.24%	-46.10%	51.72%	151.31%	-50.03%
Accounts Receivable	122.37	103.91	88.31	98.86	109.95	94.91
Other Receivables	0.66	-	8.75	1.42	4.76	7.32
Receivables	123.04	103.91	97.06	100.27	114.71	102.23
Inventory	81.29	75.76	85.32	75.41	80.63	88.02
Prepaid Expenses	12.11	9.82	4.52	15.41	47.78	18.62
Other Current Assets	2.59	1.79	1.58	2.39	13.29	13.43
Total Current Assets	950.14	830.33	619.56	993.25	783.55	432.06
Property, Plant & Equipment	452.42	430.36	424.18	434.62	465.45	481.52
Long-Term Investments	297.39	311.31	432.8	-	-	-
Other Intangible Assets	0.75	0.13	0.49	1.16	1.83	1.67
Long-Term Deferred Tax Assets	1.8	2.55	5.83	3.19	0.38	1.07
Other Long-Term Assets	5.05	7.81	10.13	15.5	13.97	40.15
Total Assets	1,708	1,582	1,493	1,448	1,265	956.47
Accounts Payable	79.09	49.98	17.17	35.94	40.15	33
Accrued Expenses	71.88	72.07	64.63	55.35	40.35	30.21
Current Portion of Leases	-	-	-	-	2.36	2.49
Current Income Taxes Payable	12.55	25.52	24.47	27.17	9.28	8.69
Current Unearned Revenue	18.56	22.93	1.34	4.25	11.13	3.76
Other Current Liabilities	44.47	35.37	23.78	28.79	12.8	8.42
Total Current Liabilities	226.55	205.87	131.37	151.5	116.07	86.58
Long-Term Leases	-	-	-	-	7.28	9.64
Long-Term Deferred Tax Liabilities	0.49	0.93	0.49	0.55	-	-
Other Long-Term Liabilities	6.97	0.56	0.02	0.02	0.12	0.02
Total Liabilities	234.01	207.36	131.88	152.07	123.47	96.24
Common Stock	896.8	891.63	889.34	846.99	769.99	694.65
Additional Paid-In Capital	329.03	326.93	296.1	281.9	264.39	89.18
Retained Earnings	450.83	344.12	244.46	169.8	110.3	79.38
Comprehensive Income & Other	-203.11	-187.56	-68.79	-3.04	-2.96	-2.99
Total Common Equity	1,474	1,375	1,361	1,296	1,142	860.23
Shareholders' Equity	1,474	1,375	1,361	1,296	1,142	860.23
Total Liabilities & Equity	1,708	1,582	1,493	1,448	1,265	956.47
Total Debt	-	-	-	-	9.64	12.13
Net Cash (Debt)	731.12	639.05	431.08	799.76	517.51	197.63
Net Cash Growth	34.46%	48.24%	-46.10%	54.54%	161.86%	3.72%
Net Cash Per Share	8.11	7.12	4.82	8.95	6.12	2.45
Filing Date Shares Outstanding	89.68	89.16	88.93	88.93	88.93	80.23
Total Common Shares Outstanding	89.68	89.16	88.93	88.93	88.93	80.23
Working Capital	723.59	624.47	488.19	841.75	667.49	345.47
Book Value Per Share	16.43	15.42	15.30	14.57	12.84	10.72
Tangible Book Value	1,473	1,375	1,361	1,294	1,140	858.55
Tangible Book Value Per Share	16.42	15.42	15.30	14.56	12.82	10.70
Land	133.23	133.23	133.23	133.23	133.23	133.23
Buildings	312.5	310.48	307.74	303.11	302.48	301.8
Machinery	206.68	181.24	160.52	149.88	162	141.51
Construction In Progress	37.35	20.08	17.67	21.6	18.79	26.03
Leasehold Improvements	13.43	13.43	18.91	18.91	23.7	21.86

Source: S&P Global Market Intelligence. Standard template. Financial Sources.